Neurocrine Biosciences Inc (NASDAQ: NBIX), a neuroscience-focused, biopharmaceutical company, announced yesterday its financial results for the six months ended 30 June 2019.
The company reported total revenues for the six months ended 30 June 2019 at USD322m compared to USD168m in the year-ago period.
The firm posted a net loss of USD50.8m or USD0.56 net loss per share for the six months ended 30 June 2019 compared to a net loss of USD47.7m or USD0.53 loss per share for the same period in 2018.
The increase in net loss for the first half of 2019 is primarily due to USD118.1m of in-process research and development (IPR&D) in connection with the strategic collaboration with Voyager. This was partially offset by increased INGREZZA net product sales and a USD22.6m unrealized gain on the company's equity investment in Voyager.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government